The bill amends the International Organizations Immunities Act by adding a new section that authorizes the President to extend the Act’s privileges and immunities to the European Organization for Nuclear Research (CERN). It delegates to the executive branch the power to determine the terms and conditions of any extension and directs that treatment be no less favourable than that applied to organizations in which the United States participates under treaty or statute.
This is a narrowly targeted statutory change with outsized operational effects: if the President acts, CERN could gain the suite of protections the IOIA makes available (legal immunities, tax and customs exemptions, inviolability of premises and certain privileges for staff), smoothing U.S. site operations and partnerships while raising questions about oversight, state and local tax impacts, and access to remedies for injured parties.
At a Glance
What It Does
Adds a new section to the IOIA authorizing the President to extend the Act’s protections to CERN, on terms the President sets and ‘‘in the same manner, to the same extent, and subject to the same conditions’’ as those applied to public international organizations in which the United States participates. The authorization is discretionary rather than mandatory.
Who It Affects
Directly affects CERN and its personnel, U.S. research institutions and firms that partner with CERN, the State Department and other executive agencies that would negotiate and implement the arrangements, and state and local governments that could lose tax or regulatory reach over exempted activity.
Why It Matters
It creates an executive path to grant long-standing international-organization benefits to a major non-U.S. scientific body, lowering administrative and legal friction for cross-border research while setting a precedent for how the U.S. treats multinational science institutions that are not formal treaty partners.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a single new provision into the International Organizations Immunities Act giving the President authority to extend that statute’s benefits to CERN. It does not itself list specific privileges; instead it enables the executive to apply the IOIA’s existing package of immunities and exemptions to CERN by formal action.
Under current practice, the IOIA is the federal statute that supplies a predictable set of legal and fiscal accommodations to international organizations and their staff—examples include immunity from certain civil suits, exemptions from federal and state taxation, customs and import concessions, and protections for official premises and archives. This bill does not rewrite those benefits; it simply makes them legally available to CERN if the President decides to grant them and specifies that any grant must be comparable to treatment the United States gives organizations where it participates under treaty or statute.Practically, implementation will be an executive-branch process: the President (typically through the State Department in coordination with Treasury, Justice, and relevant science agencies) would negotiate and announce the terms.
The bill itself imposes no funding, timeline, or procedural constraints—no mandatory reporting to Congress, no statutory criteria for when immunities are appropriate, and no automatic effect without an affirmative presidential determination.If exercised, the authority would reduce administrative barriers for CERN-operated activities on U.S. soil (for example, U.S. offices, visiting scientists, equipment imports, and collaborative facilities), while also limiting the ability of private parties and some governmental actors to bring claims or collect taxes in ways that would otherwise apply. The statute stops short of altering immigration, visa, or direct funding authorities; those remain subject to separate laws and agreements.
The Five Things You Need to Know
The bill adds a new Section 21 to the International Organizations Immunities Act specifically authorizing the President to extend that Act’s provisions to CERN.
The authorization is discretionary: the President ‘‘is authorized’’ to extend protections and must do so ‘‘under such terms and conditions as the President shall determine.’, Any extension must be ‘‘in the same manner, to the same extent, and subject to the same conditions’’ as protections the United States provides to international organizations in which it participates under treaty or by statute.
The bill contains no appropriations, no statutory criteria for approving an extension, no required congressional notification, and no mandated reporting or oversight provisions tied to the decision.
Because the text references the ‘‘provisions of this title,’’ the practical scope is the IOIA’s existing benefits—immunity from certain suits, tax and customs exemptions, inviolability of premises, and staff privileges—subject to the terms the President sets.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This single-line section gives the Act the public name "Strengthening Science Through Diplomacy Act of 2025." It has no legal effect on substance but signals the legislative intent to frame the measure as a tool of science diplomacy rather than a general expansion of immunities.
Adds authority to extend IOIA protections to CERN
This is the operative change: the bill appends a new statutory section to 22 U.S.C. 288 et seq. authorizing the President to extend the IOIA’s benefits to the Conseil Européen pour la Recherche Nucléaire (CERN). The text ties any extension to the same ‘‘manner, extent, and conditions’’ that apply when the United States participates in an organization by treaty or statute, effectively importing parity language rather than creating a bespoke list of benefits.
Presidential discretion and parity constraint
The new provision has two structural features: broad presidential discretion (the President sets ‘‘terms and conditions’’) and a parity constraint (the extension cannot be less than treatment given to organizations where the U.S. participates under treaty or statutory authority). Practically, that means the executive branch negotiates specifics—likely via State, with input from Justice and Treasury—and must align the result with existing U.S. practice for similarly situated international organizations, but Congress places no statutory check within this short amendment.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- CERN — Gains access to the IOIA framework, which can simplify establishing offices, protect premises and archives, and shield certain activities from local taxation and suit if the President extends protections.
- U.S. research universities and national labs partnering with CERN — Encounter lower administrative friction for joint projects, visiting researchers, and equipment transfers when partners and facilities receive predictable immunities and customs relief.
- U.S. federal science agencies (e.g., DOE, NSF) — Benefit from a clearer legal regime for international collaboration and reduced negotiation overhead when executing multinational research programs with CERN.
- Scientific community and industry collaborators — Stand to gain from faster project startup, easier cross-border staffing, and reduced transactional risk when CERN operations in the United States are governed by IOIA-style protections.
Who Bears the Cost
- State and local governments — Could lose tax revenue and regulatory reach (property, sales, or use taxes; permitting authority) to the extent immunities and exemptions are applied to CERN activities or property in the United States.
- Private plaintiffs and potential claimants — Face diminished remedies where IOIA immunities are extended, shifting dispute resolution toward diplomatic or alternative mechanisms rather than local courts.
- Federal agencies (Justice, Treasury, State) — Incur administrative and legal burdens to negotiate, implement, and defend the terms of any extension, and to coordinate interagency policy where domestic interests (law enforcement, taxation) intersect.
- U.S. taxpayers — May indirectly shoulder costs if immunities increase the risk that government or contractors absorb liabilities that would otherwise be paid by the organization or its insurers.
Key Issues
The Core Tension
The bill balances two legitimate goals—removing friction for high-value international scientific collaboration and preserving legal accountability and fiscal authority—by giving the President broad authority to decide which wins. The central dilemma is whether unilateral executive flexibility is the best tool to invite scientific cooperation when that same flexibility can curtail court remedies and local tax or regulatory power without a statutory framework for oversight or redress.
The amendment delegates substantial judgment to the President without establishing statutory criteria, timelines, or transparency requirements. That design accelerates executive flexibility—useful for diplomacy and rapid operational decisions—but it also raises questions about how the executive will document and justify decisions that affect state tax bases, local regulation, and the legal rights of private parties.
Another tension concerns accountability and remedies. IOIA-style immunities are meant to protect international functions, yet extending those protections to a major scientific body could shield operational conduct that causes private harm or public safety concerns.
The bill relies on the executive’s ability to calibrate terms and conditions, including possible waivers or limitations, but leaves the mechanics of waivers, dispute resolution, and remedial pathways to non-statutory instruments or negotiations.
Finally, there is a precedent risk: treating a non-treaty, non-participating international research organization like a formal participant in U.S.-style immunities could encourage similar requests from other multinational institutions, creating cumulative fiscal and legal effects for states and municipalities. The absence of reporting or congressional checkpoints means those cumulative effects could materialize incrementally and unevenly.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.